12.79
前日終値:
$12.73
開ける:
$12.58
24時間の取引高:
1.23M
Relative Volume:
0.49
時価総額:
$4.08B
収益:
$3.05B
当期純損益:
$181.32M
株価収益率:
34.23
EPS:
0.3737
ネットキャッシュフロー:
$225.64M
1週間 パフォーマンス:
-0.23%
1か月 パフォーマンス:
+7.93%
6か月 パフォーマンス:
+22.63%
1年 パフォーマンス:
+65.03%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals Inc
|
12.79 | 4.06B | 3.05B | 181.32M | 225.64M | 0.3737 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.30 | 51.84B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
113.83 | 49.05B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.30 | 42.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.38 | 36.82B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
571.07 | 24.94B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | UBS | Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) is a top-ranked momentum stock: Should you buy? - MSN
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - Yahoo! Finance Canada
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
AMRX Should I Buy - Intellectia AI
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Quantisnow
Amneal 2026-2027 Upside From Biosimilars Scale - Zacks Investment Research
AMRX Valuation: What 1.69x Sales Means for Investors - Yahoo Finance
AMRX Growth Drivers: Generics, Biosimilars, and Crexont - Yahoo Finance Australia
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock - Yahoo Finance
Amneal initiates nationwide settlement for opioid-related claims - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown - Yahoo Finance
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story - Sahm
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal - MSN
Amneal Acquires Kashiv BioSciences for $750 Million Upfront - HarianBasis.co
Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push - MarketBeat
AMRX Price Today: Amneal Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
2DT Stock Price and Chart — TRADEGATE:2DT - TradingView
Why Is Amneal Pharmaceuticals Stock Gaining Today? - Sahm
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results - The Globe and Mail
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal agrees to buy Kashiv BioSciences - The Pharma Letter
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):